Chevre, Raphael
Soehnlein, Oliver http://orcid.org/0000-0002-7854-0694
Article History
First Online: 29 July 2021
Competing interests
: R.C. declares no competing interests. O.S. receives funding from Novo Nordisk to study the potential of chronopharmacology for the treatment of atherosclerosis; he is also inventor on patents dealing with chemokine signaling and histones in inflammation.